Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed the day trading at $8.85 down -3.80% from the previous closing price of $9.2. In other words, the price has decreased by -$3.80 from its previous closing price. On the day, 1.97 million shares were traded. AVDL stock price reached its highest trading level at $9.555 during the session, while it also had its lowest trading level at $8.755.
Ratios:
For a better understanding of AVDL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.33 and its Current Ratio is at 2.73. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On June 12, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $27.
Oppenheimer reiterated its Outperform rating for the stock on March 05, 2024, while the target price for the stock was revised from $27 to $29.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 857569408 and an Enterprise Value of 830037568. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.41 while its Price-to-Book (P/B) ratio in mrq is 11.55. Its current Enterprise Value per Revenue stands at 4.269 whereas that against EBITDA is -50.612.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.44, which has changed by -0.36285096 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $17.30, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is -3.08%, while the 200-Day Moving Average is calculated to be -11.97%.
Shares Statistics:
Over the past 3-months, AVDL traded about 1.37M shares per day on average, while over the past 10 days, AVDL traded about 2180220 shares per day. A total of 96.63M shares are outstanding, with a floating share count of 88.51M. Insiders hold about 8.65% of the company’s shares, while institutions hold 77.00% stake in the company. Shares short for AVDL as of 1749772800 were 10615388 with a Short Ratio of 7.74, compared to 1747267200 on 10761809. Therefore, it implies a Short% of Shares Outstanding of 10615388 and a Short% of Float of 12.8.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Avadel Pharmaceuticals plc (AVDL) in the stock market is under the watchful eye of 3.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.1, with high estimates of $0.15 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.29 and $0.09 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $0.72, with 4.0 analysts recommending between $1.24 and $0.46.
Revenue Estimates
7 analysts predict $61.46M in revenue for the current quarter. It ranges from a high estimate of $63.8M to a low estimate of $59M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $41.5MFor the next quarter, 7 analysts are estimating revenue of $70.61M. There is a high estimate of $72.4M for the next quarter, whereas the lowest estimate is $69.1M.
A total of 7 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $261.5M, while the lowest revenue estimate was $257.54M, resulting in an average revenue estimate of $260.08M. In the same quarter a year ago, actual revenue was $169.12MBased on 7 analysts’ estimates, the company’s revenue will be $339.28M in the next fiscal year. The high estimate is $356.5M and the low estimate is $321.2M.
